Complement Tx Announces First Patient Dosed with Drug for Study in Geographic Atrophy Secondary to AMD Gallery Complement Tx Announces First Patient Dosed with Drug for Study in Geographic Atrophy Secondary to AMDsureyya hilmi2026-03-23T16:54:57+00:0025/03/2026|Read More
CEO Q&A: Dr Ningfeng Fiona Li on Preventing the Side Effects of Cancer Treatment Gallery CEO Q&A: Dr Ningfeng Fiona Li on Preventing the Side Effects of Cancer Treatmentsureyya hilmi2026-03-23T18:00:50+00:0023/03/2026|Read More
Stevenage Bioscience Catalyst wins Best Sustainable Ecosystem Delivery of the Year at One Nucleus Awards 2026 Gallery Stevenage Bioscience Catalyst wins Best Sustainable Ecosystem Delivery of the Year at One Nucleus Awards 2026sureyya hilmi2026-03-24T11:10:53+00:0020/03/2026|Read More
CamMed Therapeutics Ltd closes pre-seed round and expands Board Gallery CamMed Therapeutics Ltd closes pre-seed round and expands Boardsureyya hilmi2026-04-16T09:29:35+01:0020/03/2026|Read More
Ternary Therapeutics secures €4.1 million seed funding to advance AI-designed molecular glues Gallery Ternary Therapeutics secures €4.1 million seed funding to advance AI-designed molecular gluessureyya hilmi2026-04-13T15:12:25+01:0012/03/2026|Read More
Stevenage Bioscience Catalyst Featured in BBC Coverage of Oxford Cambridge Growth Corridor Gallery Stevenage Bioscience Catalyst Featured in BBC Coverage of Oxford Cambridge Growth Corridorsureyya hilmi2026-02-12T12:19:20+00:0012/02/2026|Read More
Aerska Raises $39M Series A Financing to Deliver RNA Medicines to the Brain Gallery Aerska Raises $39M Series A Financing to Deliver RNA Medicines to the Brainsureyya hilmi2026-04-13T15:08:13+01:0009/02/2026|Read More
Welcome Afortiori Bio to Stevenage Bioscience Catalyst Gallery Welcome Afortiori Bio to Stevenage Bioscience Catalystsureyya hilmi2026-02-06T16:45:43+00:0006/02/2026|Read More
Complement Therapeutics Receives UK CTA Approval to Advance CTx001 into Opti-GAIN Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD Gallery Complement Therapeutics Receives UK CTA Approval to Advance CTx001 into Opti-GAIN Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMDsureyya hilmi2026-01-28T18:03:13+00:0029/01/2026|Read More
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s Gallery NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’ssureyya hilmi2026-01-08T12:53:41+00:0008/01/2026|Read More
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD Gallery Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMDsureyya hilmi2026-01-08T12:54:07+00:0008/01/2026|Read More
TauC3 Biologics secures $2.5 million to advance novel treatment approach for neurodegenerative disease Gallery TauC3 Biologics secures $2.5 million to advance novel treatment approach for neurodegenerative diseasesureyya hilmi2025-12-08T09:56:57+00:0008/12/2025|Read More
Unravel Health joins SBC to drive innovation in women’s hormonal health Gallery Unravel Health joins SBC to drive innovation in women’s hormonal healthsureyya hilmi2025-12-02T11:35:30+00:0003/12/2025|Read More
SymphoRNA establishes presence at SBC to advance next generation RNA therapeutics Gallery SymphoRNA establishes presence at SBC to advance next generation RNA therapeuticssureyya hilmi2025-12-02T11:18:16+00:0002/12/2025|Read More
Anomer Bio arrives at SBC to develop a new class of glycan-targeting therapeutics Gallery Anomer Bio arrives at SBC to develop a new class of glycan-targeting therapeuticssureyya hilmi2025-12-02T11:03:44+00:0001/12/2025|Read More
SBC welcomes ‘virtual scientists’ in first-of-its-kind AI partnership to speed UK biotech innovation Gallery SBC welcomes ‘virtual scientists’ in first-of-its-kind AI partnership to speed UK biotech innovationsureyya hilmi2025-11-24T16:25:11+00:0017/11/2025|Read More
A warm welcome to LifeArc’s new Industrial Placement (IP) students Gallery A warm welcome to LifeArc’s new Industrial Placement (IP) studentssureyya hilmi2025-10-28T16:06:20+00:0028/10/2025|Read More
Santo Therapeutics Raises Multi-Million (GBP-Equivalent) Round Led by FIRHealth Capital Gallery Santo Therapeutics Raises Multi-Million (GBP-Equivalent) Round Led by FIRHealth Capitalsureyya hilmi2025-10-09T10:39:00+01:0009/10/2025|Read More
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD Gallery Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMDsureyya hilmi2025-10-08T09:56:16+01:0008/10/2025|Read More
Aerska, a biotech focused on neurological disease, has chosen SBC as its UK base of lab operations Gallery Aerska, a biotech focused on neurological disease, has chosen SBC as its UK base of lab operationssureyya hilmi2025-10-13T15:00:35+01:0001/10/2025|Read More
